162 related articles for article (PubMed ID: 8272153)
1. Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: a preliminary report.
Jurga L; Misurová E; Vancík J
Neoplasma; 1993; 40(4):259-62. PubMed ID: 8272153
[No Abstract] [Full Text] [Related]
2. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A
N Engl J Med; 1988 Sep; 319(12):745-52. PubMed ID: 3137469
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
Jelić S; Radulović S; Nesković-Konstantinović Z; Kreacić M; Ristović Z; Bosnjak S; Milanović N; Vuletić L
Support Care Cancer; 1995 May; 3(3):176-82. PubMed ID: 7655778
[TBL] [Abstract][Full Text] [Related]
5. [The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
Lichinitser MR; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Ter Arkh; 1994; 66(7):54-6. PubMed ID: 7985130
[No Abstract] [Full Text] [Related]
6. A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.
Speyer JL; Green MD; Sanger J; Zeleniuch-Jacquotte A; Kramer E; Rey M; Wernz JC; Blum RH; Hochester H; Meyers M
Cancer Treat Rev; 1990 Sep; 17(2-3):161-3. PubMed ID: 2125531
[No Abstract] [Full Text] [Related]
7. [Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].
Sauter C
Schweiz Med Wochenschr; 1994 Oct; 124(43):1879-81. PubMed ID: 7973513
[No Abstract] [Full Text] [Related]
8. [An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin].
Min'kov ED; Niu-Tian-de GB; Shkhvatsabaia LV; Bagdasarov IuB; Zaĭtseva TI; Odzharova AA
Ter Arkh; 1994; 66(10):64-6. PubMed ID: 7863453
[TBL] [Abstract][Full Text] [Related]
9. Rationale and strategy for prevention of anthracycline cardiotoxicity with the bisdioxopiperazine, ICRF-187.
Green MD
Pathol Biol (Paris); 1987 Jan; 35(1):49-53. PubMed ID: 3550612
[TBL] [Abstract][Full Text] [Related]
10. New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Am J Health Syst Pharm; 1995 Oct; 52(19):2076. PubMed ID: 8535936
[No Abstract] [Full Text] [Related]
11. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
12. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
Tonkin K; Bates M; Lieu D; Arundell E; Williamson T; Zagari M
Can J Oncol; 1996 Nov; 6(2):458-73. PubMed ID: 12056098
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide.
Kolaric K; Bradamante V; Cervek J; Cieslinska A; Cisarz-Filipcak E; Denisov LE; Donat D; Drosik K; Gershanovic M; Hudziec P
Oncology; 1995; 52(3):251-5. PubMed ID: 7715910
[TBL] [Abstract][Full Text] [Related]
14. Delayed administration of dexrazoxane provides cardioprotection against anthracyclines in breast cancer or acute myeloid leukemia.
Lemez P
J Clin Oncol; 1997 Oct; 15(10):3293-5. PubMed ID: 9336370
[No Abstract] [Full Text] [Related]
15. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
16. [Adriamycin/cyclophosphamide: current standard in the adjuvant therapy of breast carcinoma? Or: how should one really put this question?].
Cavalli F
Schweiz Med Wochenschr; 1994 Oct; 124(43):1882-4. PubMed ID: 7973514
[No Abstract] [Full Text] [Related]
17. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura GJ
J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
[No Abstract] [Full Text] [Related]
18. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
[TBL] [Abstract][Full Text] [Related]
19. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
20. Influence of smoking history on breast cancer prognosis: retrospective study of 240 operable breast cancer patients who received adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil chemotherapy regimen.
Aksoy S; Harputluoglu H; Guler N; Altundag K; Hayran M; Tekuzman G; Ozisik Y
Breast J; 2007; 13(4):431-2. PubMed ID: 17593056
[No Abstract] [Full Text] [Related]
[Next] [New Search]